Halaven 0.44mg/Ml Injection
Eribulin mesylate
0.44mg/ml
EISAI INC.
| Pack size | 2ml Glass Vial |
|---|---|
| Dispensing mode | POM |
| Source | UK |
| Agent | Modern Pharmaceutical Co. |
| Retail Price | 2416.00 AED |
Indications
Halaven 0.44mg/Ml Injection is used for:
For the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic cancer.
Adult Dose
Child Dose
Renal Dose
Administration
Contra Indications
Precautions
Pregnancy-Lactation
Interactions
Adverse Effects
Side effects of Eribulin mesylate :
Mechanism of Action
Eribulin inhibits the growth phase of microtubules without affecting the shortening phase and sequesters tubulin into nonproductive aggregates. Eribulin exerts its effects via a tubulin-based antimitotic mechanism leading to G2/M cell-cycle block, disruption of mitotic spindles, and, ultimately, apoptotic cell death after prolonged mitotic blockage. [FDA]
Note
Halaven 0.44mg/Ml 0.44mg/ml Injection manufactured by EISAI INC.. Its generic name is Eribulin mesylate. Halaven 0.44mg/Ml is availble in United Arab Emirates.
Farmaco UAE drug index information on Halaven 0.44mg/Ml Injection is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.